RadNet (NASDAQ:RDNT) Stock Gets Downgrade from Zacks Research

RadNet (NASDAQ:RDNT) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Monday, Zacks reports.

Other equities analysts have also issued reports about the company. Raymond James Financial reaffirmed a “strong-buy” rating on shares of RadNet in a research note on Tuesday, September 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of RadNet in a research report on Wednesday, November 4th. Jefferies Financial Group reaffirmed a “buy” rating on shares of RadNet in a research report on Friday, July 31st. Truist Financial increased their target price on RadNet from $90.00 to $94.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, KeyCorp boosted their price objective on RadNet from $92.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $90.43.

RadNet Price Performance

RDNT stock opened at $77.94 on Monday. The company has a market capitalization of $6.13 billion, a P/E ratio of -268.76 and a beta of 1.42. The company has a fifty day moving average price of $72.69 and a 200-day moving average price of $65.45. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.48 and a current ratio of 1.49. RadNet has a 52-week low of $50.82 and a 52-week high of $85.84.

RadNet (NASDAQ:RDNT) last issued its quarterly earnings data on Sunday, November 8th. The medical research company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.08. The company had revenue of $638.26 million for the quarter, compared to analysts’ expectations of $639.97 million. RadNet had a negative net margin of 0.94% and a positive return on equity of 3.14%. RadNet’s revenue for the quarter was up 22.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.20 earnings per share. As a group, equities analysts expect that RadNet will post 0.49 EPS for the current year.

Hedge Funds Weigh In On RadNet

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. bought a new position in shares of RadNet in the second quarter valued at approximately $675,768,000. JB Capital Partners LP bought a new stake in RadNet during the second quarter worth $87,821,842. Bamco Inc. NY bought a new stake in RadNet during the second quarter worth $77,765,000. Punch & Associates Investment Management Inc. bought a new stake in RadNet during the second quarter worth $39,054,000. Finally, Deutsche Bank AG bought a new position in RadNet in the 2nd quarter valued at $30,586,000. Hedge funds and other institutional investors own 77.90% of the company’s stock.

RadNet News Summary

Here are the key news stories impacting RadNet this week:

• Positive Sentiment: RadNet reported third-quarter EPS of $0.30, above the $0.22 consensus, while revenue rose 22.1% year over year. It also raised its 2026 revenue outlook to $2.5 billion–$2.6 billion; reports described this as the third consecutive quarterly guidance increase. RadNet Q3 earnings and outlook
• Positive Sentiment: The planned ONRAD acquisition would give RadNet direct access to more than 225 hospitals and expand its inpatient reach. One analysis said ONRAD’s EBITDA margins above 30% could make the deal margin-accretive. Separately, Digital Health’s year-to-date contract value reached $108 million. RadNet: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: KeyCorp raised its price target to $95 from $92 and maintained an Overweight rating, signaling analyst confidence in further upside. KeyCorp stock recommendations
• Neutral Sentiment: A short-interest report stated that short interest totaled zero shares as of November 10, despite describing it as a large increase. The reported figure and description appear inconsistent, so this is not a clear trading signal.
• Negative Sentiment: Quarterly revenue of $638.26 million came in slightly below the $639.97 million analyst estimate, and RadNet reported a negative net margin. These factors may have offset some of the otherwise strong results.

About RadNet

RadNet, Inc. operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging. The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.